Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Nverify (what is YN ?)
Infobox references
Chemical compound
Monomethyl auristatin E (MMAE) is a synthetic antineoplastic agent. Because of its toxicity, it cannot be used as a drug itself; instead, it is linked to a monoclonal antibody (MAB) which directs it to the cancer cells. In International Nonproprietary Names for MMAE-MAB-conjugates, the name vedotin refers to MMAE plus its linking structure to the antibody.[1] It is a potent antimitotic drug derived from peptides occurring in marine shell-less mollusc Dolabella auricularia called dolastatins which show potent activity in preclinical studies, both in vitro and in vivo, against a range of lymphomas, leukemia and solid tumors. These drugs show potency of up to 200 times that of vinblastine, another antimitotic drug used for Hodgkin lymphoma as well as other types of cancer.[2]
MMAE is actually desmethyl-auristatin E; that is, the N-terminal amino group has only one methyl substituent instead of two as in auristatin E itself.[2]
^Statement on a nonproprietary name adopted by the USAN Council: Vedotin
^ abDosio, F.; Brusa, P.; Cattel, L. (2011). "Immunotoxins and Anticancer Drug Conjugate Assemblies: The Role of the Linkage between Components". Toxins. 3 (12): 848–883. doi:10.3390/toxins3070848. PMC 3202854. PMID 22069744.
and 19 Related for: Monomethyl auristatin E information
MonomethylauristatinE (MMAE) is a synthetic antineoplastic agent. Because of its toxicity, it cannot be used as a drug itself; instead, it is linked...
Monomethylauristatin is any of a group of synthetic antineoplastic agents derived from the sea slug Dolabella auricularia: MonomethylauristatinE Monomethyl...
Monomethylauristatin F (MMAF) is a synthetic antineoplastic agent. It is part of the approved drug belantamab mafodotin in multiple myeloma and some...
of tisotumab, a monoclonal antibody against tissue factor, and monomethylauristatinE (MMAE), a potent inhibitor of cell division. It is administered...
para-aminobenzylcarbamate spacers to three to five units of the antimitotic agent monomethylauristatinE (MMAE, reflected by the 'vedotin' in the drug's name). The peptide-based...
average of three to four molecules of the chemotherapeutic agent monomethylauristatinE (MMAE). It was in Phase II clinical trials as of February 2016[update]...
called in the Philippines Lukot or Lokot. The anti-cancer agent monomethylauristatinE is derived from peptides found in D. auricularia. In Samoa it is...
ADC: An antibody-drug conjugate (ADC) with a strong cytotoxin, monomethylauristatinE, designed to treat EGFR-positive tumors, including those with KRAS...
antibody recognizing extracellular ROR1, a cleavable linker and monomethylauristatinE has entered clinical trials for the treatment of lymphoid malignancies...
human IgG2 monoclonal antibody glembatumumab (CR011) is linked to monomethylauristatinE (MMAE).[citation needed] It uses a valine-citrulline enzyme-cleavable...
conjugate (ADC) 0BI-999 was additionally developed, linking OBI-888 to monomethylauristatinE, a synthetic antineoplastic agent. The ADC is currently undergoing...
monoclonal antibody, vorsetuzumab, conjugated with noncleavable monomethylauristatin F (MMAF), a cytotoxic agent.[citation needed] This drug was developed...
Trabectedin, aplidine, didemnin, were isolated from sea squirts. MonomethylauristatinE is a derivative of a dolastatin 10, a compound made by Dolabella...
monoclonal antibody (depatuxizumab) conjugated to the tubulin inhibitor monomethylauristatin F via a stable maleimidocaproyl link. This drug was developed by...
non-Hodgkin lymphoma. It consists of an anti-CD19 mAb linked to monomethylauristatin F (MMAF), a cytotoxic agent. This drug was developed by Seattle...
antigen (BCMA) conjugated with a cytotoxic agent, maleimidocaproyl monomethylauristatin F (mcMMAF). The antibody-drug conjugate binds to BCMA on myeloma...
Global Information
verify (what is 
?)
